Sigilon Therapeutics, Inc. Contracts & Agreements

Sigilon Therapeutics, Inc. Non-Employee Director Compensation Policy, as amended on May 23, 2023 (Filed With SEC on August 7, 2023)

Sigilon Therapeutics, Inc. 2020 Employee Stock Purchase Plan, as amended on May 23, 2023 (Filed With SEC on August 7, 2023)

Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan, as amended on May 23, 2023 (Filed With SEC on August 7, 2023)

Sigilon Therapeutics, Inc. 2016 Equity Incentive Plan, as amended on May 23, 2023 (Filed With SEC on August 7, 2023)

Form of Contingent Value Right Agreement, by and among Eli Lilly and Company and a rights agent selected by Eli Lilly and Company and reasonably acceptable to Sigilon... (Filed With SEC on June 29, 2023)

Agreement and Plan of Merger, dated as of June 28, 2023, among Eli Lilly and Company, Shenandoah Acquisition Corporation and Sigilon Therapeutics, Inc (Filed With SEC on June 29, 2023)

Form of Restricted Stock Unit Agreement under the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan (Filed With SEC on March 14, 2023)

Offer Letter, between Sigilon Therapeutics, Inc. and Josias Pontes, dated October 23, 2019 (Filed With SEC on March 14, 2023)

Offer Letter, between Sigilon Therapeutics, Inc. and Sarah Yuan, dated January 12, 2022 (Filed With SEC on March 14, 2023)

Letter Agreement, dated February 10, 2023, between the Company and May Orfali, M.D (Filed With SEC on March 14, 2023)

Consulting Agreement, dated February 14, 2023, between the Company and May Orfali, M.D (Filed With SEC on March 14, 2023)

First Amendment to Research Collaboration and Exclusive License Agreement by and among Sigilon Therapeutics, Inc. and Eli Lilly and Company, dated May 5, 2022 (Filed With SEC on August 4, 2022)

Letter Agreement, dated August 4, 2021, between the Company and Deya Corzo, M.D (Filed With SEC on March 14, 2022)

Sixth Amendment to Exclusive Patent License Agreement, by and between Massachusetts Institute of Technology and Sigilon Therapeutics, Inc., dated February 1, 2022 (Filed With SEC on March 14, 2022)

Offer Letter, between Sigilon Therapeutics, Inc. and May Orfali, M.D. dated October 27, 2021 (Filed With SEC on March 14, 2022)

Offer Letter, between Sigilon Therapeutics, Inc. and Philip Ashton-Rickardt, dated May 25, 2021 (Filed With SEC on March 14, 2022)

Offer Letter, between Sigilon Therapeutics, Inc. and Deya Corzo, M.D. dated September 26, 2018 (Filed With SEC on March 14, 2022)

Consulting Agreement, dated October 13, 2021, between the Company and May Orfali, M.D (Filed With SEC on March 14, 2022)

Fifth Amendment to Exclusive Patent License Agreement, by and between Massachusetts Institute of Technology and Sigilon Therapeutics, Inc., dated September 17, 2021 (Filed With SEC on November 10, 2021)

Consulting Agreement between Sigilon Therapeutics, Inc. and Devyn Smith, dated April 26, 2021 (Filed With SEC on August 10, 2021)

Fourth Amendment to Exclusive Patent License Agreement, by and between Massachusetts Institute of Technology and Sigilon Therapeutics, Inc., dated December 10, 2020 (Filed With SEC on March 18, 2021)

Second Amendment to Lease, by and among ARE-MA Region No. 45, LLC and Sigilon Therapeutics, Inc., dated January 19, 2021 (Filed With SEC on March 18, 2021)

Description of Registered Securities (Filed With SEC on March 18, 2021)

Form of Underwriting Agreement (Filed With SEC on November 30, 2020)

Sigilon Therapeutics, Inc. 2020 Employee Stock Purchase Plan (Filed With SEC on November 30, 2020)

Form of Incentive Stock Option Agreement (Filed With SEC on November 30, 2020)

Form of Non-Statutory Stock Option Agreement (Employees) (Filed With SEC on November 30, 2020)

Form of Non-Statutory Stock Option Agreement (Non-Employee Directors) (Filed With SEC on November 30, 2020)

Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan (Filed With SEC on November 30, 2020)

Research Collaboration and Exclusive License Agreement, by and between Sigilon Therapeutics, Inc. and Eli Lilly and Company, dated April 2, 2018 (Filed With SEC on November 13, 2020)

Third Amended and Restated Investors' Rights Agreement, by and among Sigilon Therapeutics, Inc. and the investors party thereto, dated as of October 23, 2020 (Filed With SEC on November 13, 2020)

Warrant to Purchase Stock, between Sigilon Therapeutics, Inc. and Pacific Western Bank, dated January 24, 2018 (Filed With SEC on November 13, 2020)

Warrant to Purchase Stock, between Sigilon Therapeutics, Inc. and Pacific Western Bank, dated November 7, 2019 (Filed With SEC on November 13, 2020)

Form of Warrant to Purchase Stock, between Sigilon Therapeutics, Inc. and Oxford Finance LLC, dated September 2, 2020 (Filed With SEC on November 13, 2020)

Lease, by and between ARE-MA Region No. 45, LLC and Sigilon Therapeutics, Inc., dated August 28, 2017 (Filed With SEC on November 13, 2020)

Lease Agreement, by and between ARE-MA Region No. 45, LLC and Foghorn Therapeutics Inc., dated August 24, 2017 (Filed With SEC on November 13, 2020)

Assignment and Assumption of Lease, by and between Foghorn Therapeutics Inc. and Sigilon Therapeutics, Inc., dated October 21, 2019 (Filed With SEC on November 13, 2020)

Consent to Assignment and First Amendment to Lease, by and among ARE-MA Region No. 45, LLC, Foghorn Therapeutics Inc. and Sigilon Therapeutics, Inc., dated October 21, 2019 (Filed With SEC on November 13, 2020)

Loan and Security Agreement, by and among Oxford Finance LLC, the Lenders party thereto, and Sigilon Therapeutics, Inc., dated September 2, 2020 (Filed With SEC on November 13, 2020)

Exclusive Patent License Agreement, by and between Massachusetts Institute of Technology and Sigilon Therapeutics, Inc., dated February 8, 2016 (Filed With SEC on November 13, 2020)

First Amendment to Exclusive Patent License Agreement, by and between Massachusetts Institute of Technology and Sigilon Therapeutics, Inc., dated February 2, 2017 (Filed With SEC on November 13, 2020)

Second Amendment to Exclusive Patent License Agreement, by and between Massachusetts Institute of Technology and Sigilon Therapeutics, Inc., dated August 9, 2018 (Filed With SEC on November 13, 2020)

Third Amendment to Exclusive Patent License Agreement, by and between Massachusetts Institute of Technology and Sigilon Therapeutics, Inc., dated November 6, 2019 (Filed With SEC on November 13, 2020)

Specimen stock certificate evidencing shares of common stock (Filed With SEC on November 13, 2020)

Sigilon Therapeutics, Inc. 2016 Stock Option and Grant Equity Incentive Plan, as amended (Filed With SEC on November 13, 2020)

Form of Incentive Stock Option Agreement under the Sigilon Therapeutics, Inc. 2016 Equity Incentive Plan (Filed With SEC on November 13, 2020)

Form of Nonstatutory Stock Option Agreement under the Sigilon Therapeutics, Inc. 2016 Equity Incentive Plan (Filed With SEC on November 13, 2020)

Offer Letter, between Sigilon Therapeutics, Inc. and Rogerio Vivaldi Coelho, M.D., dated April 23, 2018 (Filed With SEC on November 13, 2020)

Offer Letter, between Sigilon Therapeutics, Inc. and Glenn Reicin, dated May 8, 2019 (Filed With SEC on November 13, 2020)

Offer Letter, between Sigilon, Inc. and Devyn Smith, dated March 25, 2017 (Filed With SEC on November 13, 2020)

Severance Waiver and Offer Letter Amendment, between Sigilon Therapeutics, Inc. and Rogerio Vivaldi Coelho, M.D., dated October 26, 2020 (Filed With SEC on November 13, 2020)

Form of Non-Chief Executive Officer Severance Waiver and Offer Letter Amendment (Filed With SEC on November 13, 2020)

Stock Restriction Agreement, between Sigilon Therapeutics, Inc. and Daniel G. Anderson, dated February 10, 2016 (Filed With SEC on November 13, 2020)

Stock Restriction Agreement, between Sigilon Therapeutics, Inc. and Robert S. Langer, dated February 5, 2016 (Filed With SEC on November 13, 2020)

Sigilon Therapeutics, Inc. Amended and Restated Severance and Change in Control Policy (Filed With SEC on November 13, 2020)

Sigilon Therapeutics, Inc. 2020 Cash Incentive Plan (Filed With SEC on November 13, 2020)

Sigilon Therapeutics, Inc. Non-Employee Director Compensation Policy (Filed With SEC on November 13, 2020)